One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
What evidence is needed to demonstrate the beneficial effects of exercise for osteoarthritis?
Margreet Kloppenburg, François Rannou, Francis Berenbaum
doi : 10.1136/annrheumdis-2021-221685
April 2022 - Volume 81 - 4
Cutaneous signs and mechanisms of inflammasomopathies
Carina Borst, Dörte Symmank, Mathias Drach, Wolfgang Weninger
No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?
Juergen Braun, Robert BM Landewé
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study
Evgeniy Nasonov, Saeed Fatenejad, Eugen Feist, Mariana Ivanova, Elena Korneva, Diana G Krechikova, Aleksey L Maslyanskiy, Mikhail Samsonov, Rumen Stoilov, Elena V Zonova, Mark Genovese
Key interactions in the trimolecular complex consisting of the rheumatoid arthritis-associated DRB1*04:01 molecule, the major glycosylated collagen II peptide and the T-cell receptor
Changrong Ge, Sylvia Weisse, Bingze Xu, Doreen Dobritzsch, Johan Viljanen, Jan Kihlberg, Nhu-Nguyen Do, Nadine Schneider, Harald Lanig, Rikard Holmdahl, Harald Burkhardt
Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis
Sayam Dubash, Oras A Alabas, Xabier Michelena, Leticia Garcia-Montoya, Richard J Wakefield, Philip S Helliwell, Paul Emery, Dennis G McGonagle, Ai Lyn Tan, Helena Marzo-Ortega
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
David Jayne, Brad Rovin, Eduardo F Mysler, Richard A Furie, Frederic A Houssiau, Teodora Trasieva, Jacob Knagenhjelm, Erik Schwetje, Yen Lin Chia, Raj Tummala, Catharina Lindholm
Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire
Mike O Becker, Rucsandra Dobrota, Alexandru Garaiman, Rudolf Debelak, Kim Fligelstone, Ann Tyrrell Kennedy, Annelise Roennow, Yannick Allanore, Patricia E Carreira, László Czirják, Christopher P Denton, Roger Hesselstrand, Gunnel Sandqvist, Otylia Kowal-Bielecka, Cosimo Bruni, Marco Matucci-Cerinic, Carina Mihai, Ana Maria Gheorghiu, Ulf Mueller-Ladner, Joseph Sexton, Tore K Kvien, Turid Heiberg, Oliver Distler
Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time
Brian Skaug, Marka A Lyons, William R Swindell, Gloria A Salazar, Minghua Wu, Tuan M Tran, Julio Charles, Connor P Vershel, Maureen D Mayes, Shervin Assassi
Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis
Marc Corbera-Bellalta, Roser Alba-Rovira, Sujatha Muralidharan, Georgina EspÃgol-Frigolé, Roberto RÃos-Garcés, Javier Marco-Hernández, Amanda Denuc, Farah Kamberovic, Patricia Pérez-Galán, Alexandra Joseph, Annalisa D’Andrea, Kent Bondensgaard, Maria C Cid, John F Paolini
Exercise and education versus saline injections for knee osteoarthritis: a randomised controlled equivalence trial
Elisabeth Bandak, Robin Christensen, Anders Overgaard, Lars Erik Kristensen, Karen Ellegaard, Jørgen Guldberg-Møller, Cecilie Bartholdy, David J Hunter, Roy Altman, Henning Bliddal, Marius Henriksen
Digoxin targets low density lipoprotein receptor-related protein 4 and protects against osteoarthritis
Kai-di Wang, Xiang Ding, Nan Jiang, Chao Zeng, Jing Wu, Xian-yi Cai, Aubryanna Hettinghouse, Asya Khleborodova, Zi-Ning Lei, Zhe-Sheng Chen, Guang-hua Lei, Chuan-ju Liu
Impact of adiposity on risk of female gout among those genetically predisposed: sex-specific prospective cohort study findings over >32 years
Natalie McCormick, Chio Yokose, Na Lu, Amit D Joshi, Gary C Curhan, Hyon K Choi
Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
Xue Li, Xinning Tong, Winnie Wan Yin Yeung, Peng Kuan, Samson Hin Hei Yum, Celine Sze Ling Chui, Francisco Tsz Tsun Lai, Eric Yuk Fai Wan, Carlos King Ho Wong, Esther Wai Yin Chan, Chak Sing Lau, Ian Chi Kei Wong
Survival after COVID-19-associated organ failure among inpatients with systemic lupus erythematosus in France: a nationwide study
Arthur Mageau, Thomas Papo, Stephane Ruckly, Andrey Strukov, Damien van Gysel, Karim Sacre, Jean-François Timsit
BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus
Quentin Moyon, Delphine Sterlin, Makoto Miyara, François Anna, Alexis Mathian, Raphael Lhote, Pascale Ghillani-Dalbin, Paul Breillat, Sasi Mudumba, Sophia de Alba, Fleur Cohen-aubart, Julien Haroche, Micheline Pha, Thi Huong Du Boutin, Hedi Chaieb, Pedro Macedo Flores, Pierre Charneau, Guy Gorochov, Zahir Amoura
Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection
Zhenyu Zhong, Weiting Liao, Lingyu Dai, Xiaojie Feng, Guannan Su, Yu Gao, Qiuying Wu, Peizeng Yang
Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors
Dimitra Dimopoulou, George Vartzelis, Foteini Dasoula, Maria Tsolia, Despoina Maritsi
Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis
Claudius Speer, Maximilian Töllner, Louise Benning, Katrin Klein, Marie Bartenschlager, Christian Nusshag, Florian Kälble, Paula Reichel, Paul Schnitzler, Martin Zeier, Christian Morath, Wilhelm H Schmitt, Raoul Bergner, Ralf Bartenschlager, Matthias Schaier
Herpes zoster reactivation after mRNA-1273 vaccination in patients with rheumatic diseases
Tai-Ju Lee, Cheng-Hsun Lu, Song-Chou Hsieh
Hypoglycaemia following JAK inhibitor treatment in patients with diabetes
Jette A van Lint, Florence P A M van Hunsel, Sander W Tas, Harald E Vonkeman, Frank Hoentjen, Martijn B A van Doorn, Renske C F Hebing, Michael T Nurmohamed, Bart J F van den Bemt, Eugene P van Puijenbroek, Naomi T Jessurun
Clinical characteristics of juvenile gout and treatment response to febuxostat
Shaoling Zheng, Pui Y Lee, Yukai Huang, Weiming Deng, Zhixiang Huang, Qidang Huang, Shuyang Chen, Tianwang Li
Autoantibodies and interstitial lung disease in rheumatoid arthritis: towards a ‘mix-and-match’ approach?
Alessia Alunno, Onelia Bistoni, Angelo Francesco Bonifacio, Roberto Gerli
Response to: ‘Autoantibodies and interstitial lung disease in rheumatoid arthritis: towards a ‘mix-and-match’ approach’ by Alunno et al
Raul Castellanos-Moreira, Sebastian Cruz RodrÃguez-GarcÃa, Isabel Haro, Raimon Sanmarti
Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis
Serena Bugatti, Ludovico De Stefano, Ennio Giulio Favalli, Roberto Caporali, Carlomaurizio Montecucco
Response to: ‘Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis’ by Bugatti et al
Paul Studenic, David T Felson, Maarten de Wit, Josef S Smolen, Daniel Aletaha
Withdrawal of low-dose prednisone in inactive SLE patients: Is there another alternative?
José Mario Sabio
Response to: ‘Withdrawal of low-dose prednisone in inactive SLE patients: is there another alternative?’ by Sabio
Alexis Mathian, Micheline Pha, Zahir Amoura
External validation of EULAR/ACR classification criteria for idiopathic inflammatory myopathies
Queenie Luu, Jessica Day, Alix Hall, Vidya Limaye, Gabor Major
Response to: ‘External validation of EULAR/ACR classification criteria for idiopathic inflammatory myopathies’ by Luu et al
Masatoshi Jinnin, Akiko Ohta, Hitoshi Kohsaka
Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease
Satoshi Sato, Takahiro Hosokawa, Hisashi Kawashima
Response to: ‘Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease’ by Sato et al
Vivian E Saper, Guangbo Chen, R Paul Guillerman, Purvesh Khatri, Randy Q Cron, Elizabeth D Mellins
Is non-industrial society undergoing an energy balance transition predisposed to accumulate abdominal adipose tissue and susceptible to knee osteoarthritis?
Yang Yu, Shitao Lu, Jianzhong Xu
Response to: ‘Is non-industrial society undergoing an energy balance transition predisposed to accumulate abdominal adipose tissue and susceptible to knee osteoarthritis?’ by Yu et al
Ian J Wallace, David T Felson, Steven Worthington, Daniel E Lieberman
Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues
Daniel Riddle, Robert Perera
Response to: ‘Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues’ by Riddle and Perera
Francis Berenbaum, Francisco J Blanco, Ali Guermazi, Kenji Miki, Takaharu Yamabe, Lars Viktrup, Rod Junor, William Carey, Mark T Brown, Christine R West, Kenneth M Verburg
JAK inhibitors as promising agents for refractory Takayasu arteritis
Ryu Watanabe
Response to: ‘JAK inhibitors as promising agents for refractory Takayasu arteritis’ by Watanabe
Shun Tanimura, Hiroyuki Nakamura, Tetsuya Horita
